Table 3.
Visual Acuity and Change in Visual Acuity Throughout Follow-up for Eyes With Persistent DME Through the 24-Week Visita
| Chronic Persistent DMEb |
||||||
|---|---|---|---|---|---|---|
| 1-y Visitc |
2-y Visitd |
3-y Visite |
||||
| Variable | Yes (n = 95) | No (n = 22) | Yes (n = 61) | No (n = 48) | Yes (n = 40) | No (n = 60) |
| Baseline visual acuity, median (IQR) | ||||||
| Letter score | 66 (73 to 57) | 65 (70 to 58) | 67 (73 to 53) | 65 (70 to 59) | 67 (73 to 58) | 65 (71 to 58) |
| Approximate Snellen equivalent | 20/50 (20/40 to 20/80) | 20/50 (20/40 to 20/80) | 20/50 (20/40 to 20/100) | 20/50 (20/40 to 20/63) | 20/50 (20/40 to 20/80) | 20/50 (20/40 to 20/80) |
| Follow-up visual acuity | ||||||
| Letter score, median (IQR) | 75 (81 to 66) | 75 (81 to 69) | 74 (81 to 65) | 76 (81 to 70) | 76 (80 to 57) | 79 (83 to 72) |
| Approximate Snellen equivalent, median (IQR) | 20/32 (20/25 to 20/50) | 20/32 (20/25 to 20/40) | 20/32 (20/25 to 20/50) | 20/32 (20/25 to 20/40) | 20/32 (20/25 to 20/80) | 20/25 (20/20 to 20/40) |
| Letter score, mean (SD) | 71 (13) | 72 (12) | 70 (17) | 73 (13) | 70 (14) | 75 (13) |
| Approximate Snellen equivalent, mean (SD lines, assuming 5 letters per line) | 20/40 (2.6) | 20/40 (2.4) | 20/40 (3.4) | 20/32 (2.6) | 20/40 (2.8) | 20/32 (2.6) |
| Change in visual acuity from baseline visit | ||||||
| Letters, median (IQR) | 8 (3 to 15) | 8 (4 to 15) | 8 (2 to 17) | 11 (5 to 17) | 5 (−2 to 16) | 12 (8 to 21) |
| Letters, mean (SD) | 9 (12) | 11 (11) | 8 (17) | 11 (13) | 7 (14) | 13 (12) |
| ≥10-Letter gain, No. (%) | 42 (44.2) | 10 (45.5) | 26 (42.6) | 28 (58.3) | 17 (42.5) | 36 (60.0) |
| 5- to 9-Letter gain, No. (%) | 25 (26.3) | 4 (18.2) | 13 (21.3) | 8 (16.7) | 3 (7.5) | 14 (23.3) |
| Within ±4 letters, No. (%) | 19 (20.0) | 8 (36.4) | 15 (24.6) | 9 (18.8) | 12 (30.0) | 5 (8.3) |
| 5- to 9-Letter loss, No. (%) | 5 (5.3) | 0 | 2 (3.3) | 2 (4.2) | 3 (7.5) | 3 (5.0) |
| ≥10-Letter loss, No. (%) | 4 (4.2) | 0 | 5 (8.2) | 1 (2.1) | 5 (12.5) | 2 (3.3) |
| Change in visual acuity from 24-wk visit | ||||||
| Letters, median (IQR) | 1 (−4 to 5) | 3 (1 to 6) | 1 (−4 to 6) | 2 (−2 to 6) | 0 (−7 to 4) | 5 (−3 to 9) |
| Letters, mean (SD) | 0 (9) | 3 (6) | −1 (14) | 2 (10) | −2 (12) | 3 (10) |
| ≥10-Letter gain, No. (%) | 7 (7.4) | 4 (18.2) | 9 (14.8) | 5 (10.4) | 5 (12.5) | 13 (21.7) |
| 5- to 9-Letter gain, No. (%) | 18 (18.9) | 3 (13.6) | 10 (16.4) | 8 (16.7) | 3 (7.5) | 17 (28.3) |
| Within ±4 letters, No. (%) | 50 (52.6) | 13 (59.1) | 28 (45.9) | 28 (58.3) | 21 (52.5) | 22 (36.7) |
| 5- to 9-Letter loss, No. (%) | 11 (11.6) | 1 (4.5) | 8 (13.1) | 4(8.3) | 4 (10.0) | 5 (8.3) |
| ≥10-Letter loss, No. (%) | 9 (9.5) | 1 (4.5) | 6 (9.8) | 3 (6.3) | 7 (17.5) | 3 (5.0) |
Abbreviations: DME, diabetic macular edema; IQR, interquartile range.
All eyes had baseline central subfield thickness of 250 μm or greater, at least 4 injections before the 24-week visit, and no more than 2missed visits between the 28-week and 1-year visits.
Eyes meeting criteria for no DME at a given visit shift into the no column at that visit and remain there at subsequent visits.
Limited to participants completing the 1-year visit in the plus or minus 8-week analysis window (actual IQR, 49-54 weeks).
Limited to participants completing the 2-year visit in the plus or minus 16-week analysis window (actual IQR, 99-107 weeks) and having at least 4 visits between the 1-year and 2-year visits and no nonprotocol treatment before 2 years.
Limited to participants completing the 3-year visit in the plus or minus 16-week analysis window (actual IQR, 145-165 weeks) and having at least 4 visits between the 1-year and 2-year visits at least 4 visits between the 2-year and 3-year visits and no nonprotocol treatment before 3 years.